The small-profile device expands to capture clots like large-bore systems while offering good reduction in RV/LV ratio at 48 ...

Follow-up over 10 years may show different patterns, and experts predict DCBs will likely be useful in certain populations.

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

Patrick O’Gara speaks with Sean Pinney about the evaluation and treatment of patients with severe tricuspid regurgitation.

Mamas Mamas and Evald Christiansen discuss the 10-year data comparing DES PCI and CABG for LM disease.

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

With host Roxana Mehran, Brahmajee Nallamothu shares the best of what's to come in New Orleans.

HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

It’s the height of meeting season! All our most-read stories this month hailed from the news team’s on-site coverage.